<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726490</url>
  </required_header>
  <id_info>
    <org_study_id>E16008</org_study_id>
    <nct_id>NCT02726490</nct_id>
  </id_info>
  <brief_title>Glyburide vs Glucovance in the Treatment of GDM</brief_title>
  <acronym>GGIG</acronym>
  <official_title>Glyburide vs Glucovance in the Treatment of Gestational Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center, El Paso</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University Health Sciences Center, El Paso</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized comparison of glyburide to glucovance (metformin -glyburide) in the management
      of diabetes in pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized open label trial of glyburide compared to glucovance in the
      management of gestational diabetes. We hypothesize that glucovance will provide improved
      glycemic control and a lower failure rate with no increase in neonatal adverse outcomes.
      Sixty-seven patients will be randomized by computer to each arm of the study. Outcomes will
      be glycemic control, failure rate of the drug to achieve glycemic goals, and neonatal
      outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of glyburide compared to glucovance</measure>
    <time_frame>during the index pregnancy</time_frame>
    <description>failure rate of glyburide compared to glucovance in ability to achieve euglycemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maternal hypoglycemia</measure>
    <time_frame>during the index pregnancy</time_frame>
    <description>the rate of maternal hypoglycemia associated with each drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal birthweight</measure>
    <time_frame>at birth</time_frame>
    <description>infant weight at birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal apgar scores</measure>
    <time_frame>at birth</time_frame>
    <description>infant 1 minute and 5 minute apgar scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal admission to the newborn intensive care unit (NICU)</measure>
    <time_frame>at birth or within the first 24 hours after birth</time_frame>
    <description>admission to the Newborn intensive care unit (NICU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal hypoglycemia</measure>
    <time_frame>up to 24 hours after delivery</time_frame>
    <description>failure of the neonate to maintain blood glucose &gt; 60 milligrams/deciliter (mg/dl)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>Glyburide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.
The starting dose of glyburide may be 2.5milligrams (mg) to 5mg every day(QD) or twice daily (BID) depending on the degree of hyperglycemia.
The dose of glyburide will be increased as needed to a maximum of 20mg /day.
Antenatal testing will be initiated at 28 weeks
Patients will receive monthly growth scans</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucovance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.
The starting dose of glucovance may be 1.25/250milligrams (mg) either once daily (QD) or twice a day (BID) increased to a maximum of 20mg/2000mg as needed.
Patients will receive monthly growth scans
Antenatal testing will be initiated at 28 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyburide</intervention_name>
    <description>glyburide 2.5milligrams (mg) at bedtime (qhs) increased as needed to a maximum of 20mg/day usually taken twice a day (BID)</description>
    <arm_group_label>Glyburide</arm_group_label>
    <other_name>micronase</other_name>
    <other_name>diabeta</other_name>
    <other_name>glynase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucovance</intervention_name>
    <description>glucovance (2.5/500) 1 taken orally (PO) at bed time (QHS) increased as needed to a maximum dose of (20/2000)/day usually taken twice a day (BID)</description>
    <arm_group_label>Glucovance</arm_group_label>
    <other_name>combination glyburide and metformin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational diabetes

          -  Pregnancy &gt; 12 weeks gestation

          -  Ability to give consent

        Exclusion Criteria:

          -  Inability to consent to the study

          -  Pre-existing diabetes

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  Serum creatinine &gt;1

          -  Liver disease

          -  Allergy to sulfa;

          -  Allergy to glyburide;

          -  Allergy to metformin;

          -  Fetal anomalies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa E Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech Health Sciences Center El Paso</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa E Moore, MD</last_name>
    <phone>915-215-5100</phone>
    <email>lisa.e.moore@ttuhsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nancy Rondeau, MPH</last_name>
    <phone>915-215-5121</phone>
    <email>nancy.u.rondeau@ttuhsc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>TTUHSC El Paso</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa E Moore, M.D.</last_name>
      <phone>915-215-5100</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moore LE, Briery CM, Clokey D, Martin RW, Williford NJ, Bofill JA, Morrison JC. Metformin and insulin in the management of gestational diabetes mellitus: preliminary results of a comparison. J Reprod Med. 2007 Nov;52(11):1011-5.</citation>
    <PMID>18161398</PMID>
  </reference>
  <results_reference>
    <citation>Moore LE, Clokey D, Rappaport VJ, Curet LB. Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstet Gynecol. 2010 Jan;115(1):55-9. doi: 10.1097/AOG.0b013e3181c52132.</citation>
    <PMID>20027034</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Tech University Health Sciences Center, El Paso</investigator_affiliation>
    <investigator_full_name>Lisa E. Moore</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gestational diabetes, pregnancy, diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glyburide</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

